Location: Washington DC, United States
Date: March 17 to March 19
66th Scientific Session.
FOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk
Ivabradine in Patients With Symptomatic Inapprioprate Sinus Tachycardia: Long-Term Observational Study
SPRINT Trial in the age group >75; Fixed dose combinations; Evolution of U.S. Hypertension Guidelines
A Closer Look at Real World Evidence and the Availability of a Reversal Agent in Anticoagulation Care; Clinical Implications of Idarucizumab
EMPA-REG Outcome in clinical practice
Efficacy and Safety Profile of Ivabradine in Heart Failure Due to Chagas´ Heart Disease: A Post-Hoc Analysis of the SHIFT Trial
Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
Additivity of Nebivolol/Valsartan Single-Pill Combinations Versus Other Approved Single-Pill Combinations for Hypertension
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Active Malignancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial